Sanofi (France)
NEWS
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.
AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term infants.
Sanofi will use its manufacturing capabilities to support the development of 200 million doses of the Moderna COVID-19 vaccine beginning in September.
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
The new factory will include cutting-edge technology, allowing production of three to four vaccines simultaneously, a massive improvement on the current limitation of one vaccine in an industrial site.
Tidal Therapeutics, which does not even have a website, came out of LabCentral in Cambridge. It focuses on developing nanoparticles able to deliver messenger RNA (mRNA) that can reprogram immune cells.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
The U.S. Food and Drug Administration approved two new treatments for multiple myeloma and pulmonary hypertension.
JOBS
IN THE PRESS